Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Hemogenyx Pharmaceuticals Plc is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies primarily for blood cancers and autoimmune diseases. Founded in 2013 and headquartered in London, the company develops innovative treatments such as HG-CT-1, aimed at relapsed or refractory acute myeloid leukemia, alongside platform technologies designed to improve bone marrow and blood stem cell transplant procedures. Hemogenyx's pipeline includes therapies targeting viral infections, cancer, and neurological conditions through advanced approaches like chimeric bait receptors and bi-specific antibodies. The company operates research facilities in both the UK and the US, emphasizing breakthrough science to extend the therapeutic benefits of bone marrow transplantation to a wider patient population suffering from life-threatening diseases such as leukemia, lymphoma, multiple sclerosis, aplastic anemia, and systemic lupus erythematosus. Hemogenyx Pharmaceuticals plays a significant role in advancing treatments within the hematology and immunology sectors, addressing critical unmet medical needs with the potential to transform patient outcomes.
£7.70
+£0.20 (+2.67%)
EOD Jul 3, 2026
ROIC dropped from -98.31% to -111.15%, capital efficiency is deteriorating. Negative free cash flow of -£3M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
£0.00
Net Income (TTM)
-£10M
▼ -73.6% YoY
Op. Margin
—
ROIC
-111.15%
▼ -12.8pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-£3M
▲ +16.9% YoY
Op. Cash Flow (TTM)
-£3M
▲ +16.7% YoY
Net Debt
£418K
Cash & Equiv.
£2M
Continue Research
Hemogenyx Pharmaceuticals (HEMO.XLON)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Hemogenyx Pharmaceuticals scores 0/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Hemogenyx Pharmaceuticals scores 0 out of 100 on Intrinsiqq's quality score, a weighted blend of 4 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -111.2% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh HEMO.XLON's valuation and scores 0/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.